Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

Raffaele Marfella, Michelangela Barbieri, Rodolfo Grella, Maria Rosaria Rizzo, Giovanni Francesco Nicoletti, Giuseppe Paolisso

Research output: Contribution to journalArticlepeer-review

Abstract

There is increasing evidence that glycemic disorders such as rapid glucose fluctuations over a daily period might play an important role on diabetic complications. We evaluated the efficacy of sitagliptin 100 mg once daily vs. vildagliptin 50 mg twice daily on daily blood glucose fluctuations in patients with type 2 diabetes that was inadequately controlled by metformin. Forty-eight-hour continuous subcutaneous glucose monitoring (CSGM) was performed in patients treated with metformin plus vildagliptin (n=18) or sitagliptin (n=20) over a period of 3 months. The mean amplitude of glycemic excursions (MAGE) was used for assessing glucose fluctuations during the day. During a standardized meal, glucagon-like peptide-1 (GLP-1), glucagon, and insulin were measured. CSGM shows large MAGE decrements in the vildagliptin group compared with the sitagliptin group (P1c but also flattening acute glucose fluctuations over a daily period.

Original languageEnglish
Pages (from-to)79-83
Number of pages5
JournalJournal of Diabetes and its Complications
Volume24
Issue number2
DOIs
Publication statusPublished - Mar 2010

Keywords

  • Dipeptidyl peptidase IV-inhibitors
  • Glicemic control

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Fingerprint Dive into the research topics of 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations'. Together they form a unique fingerprint.

Cite this